US20080311210A1 - Pharmaceutical composition for use as a laxative - Google Patents

Pharmaceutical composition for use as a laxative Download PDF

Info

Publication number
US20080311210A1
US20080311210A1 US12/040,290 US4029008A US2008311210A1 US 20080311210 A1 US20080311210 A1 US 20080311210A1 US 4029008 A US4029008 A US 4029008A US 2008311210 A1 US2008311210 A1 US 2008311210A1
Authority
US
United States
Prior art keywords
composition
weight
dry extract
senna
fruit dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/040,290
Other languages
English (en)
Inventor
Wolfgang Morick
Lars-Norbert Prenner
Michael Hubbert
Kurt N. Gebhart
Wolf Behm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madaus GmbH
Original Assignee
Madaus GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus GmbH filed Critical Madaus GmbH
Assigned to MADAUS GMBH reassignment MADAUS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEHM, WOLF, HUBBERT, MICHAEL, DR., PRENNER, LARS-NORBERT, DR., GEBHART, KURT N., DR., MORRICK, WOLFGANG, DR.
Assigned to MADAUS GMBH reassignment MADAUS GMBH PLEASE SEE ATTACHED Assignors: BEHM, WOLF, HUBBERT, MICHAEL, PRENNER, LARS-NORBERT, GEBHART, KURT N., MORICK, WOLFGANG
Priority to US12/140,102 priority Critical patent/US20090110759A1/en
Publication of US20080311210A1 publication Critical patent/US20080311210A1/en
Priority to US12/420,602 priority patent/US7611736B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a novel composition, in particular pharmaceutical composition, for use as laxative (also referred to synonymously as “cathartic” or “purgative”) and to a method for its manufacture, and to the use of this composition as laxative (i.e. cathartic or purgative).
  • laxative also referred to synonymously as “cathartic” or “purgative”
  • laxative i.e. cathartic or purgative
  • Laxatives also referred to synonymously as “purgatives” or “cathartics”—exist in very diverse forms, including numerous herbal cathartics.
  • plantago seed plantaginis ovatae semen or semen plantaginis ovatae , also called synonymously Indian plantain, Indian psyllium, blond psyllium, ispaghula or semen ispaghulae
  • its seed husks plantago seed husks, plantaginis ovatae seminis integumentum
  • Plantago seed has a considerable swelling ability and exerts a physical expansion stimulus on the sensitive receptors of the bowel walls.
  • the seeds are finely ground, made into a viscous paste with water and dried in strand form, comminuted and finally coated.
  • senna plant senna plant, Cassia senna L. and Cassia angustifolia Vahl
  • its fruits fructus sennae, also referred to synonymously as senna pods
  • their fruit husks as well as their leaves (folia sennae)
  • herbal cathartic is likewise known.
  • Laxatives which combine the two aforementioned action principles are also known, for example laxatives in which the physical effect of plantago seeds is supported by the pharmacologically stimulating action principle of the sennosides, the constituents of senna fruits, in order to achieve a better overall effect.
  • laxatives in which the physical effect of plantago seeds is supported by the pharmacologically stimulating action principle of the sennosides, the constituents of senna fruits, in order to achieve a better overall effect.
  • mixtures of ground plantago seeds and senna fruits as a simple mixture in which the constituents are present side by side have previously been disclosed.
  • the flowability and suspendability in water cannot be optimally adjusted with such mixtures, but this would be desirable for oral administration. Processing of these mixtures to powders ready for administration is moreover impossible or not directly possible.
  • DE 30 01 357 C2 proposed a laxative in the form of cathartic granules based on senna fruits, plantago seeds and, where appropriate, plantago seed husks with an increased release-slowing effect, where the senna particles are enveloped or encased by plantago seeds, especially gummy sub-stances of the plantago seeds.
  • the composition described therein is an efficient laxative.
  • the composition is in the form of granules with a particle size of about 1 mm to about 3 mm of the granule particles, i.e. of asymmetric aggregates of powder particles, it must be taken with copious water.
  • WO 2005/027948 A1 and US 2005/0053676 A1 describe a laxative based on a powdered composition which, besides plantago seeds ( plantaginis ovatae semen ) and/or plantago seed husks and at least one anthranoid compound with a cathartic effect, in particular at least one sennoside, preferably in the form of anthranoid- or sennoside-containing plant constituents/parts, also comprises at least one polygalactomannan-based polysaccharide or derivative thereof, in particular guaran (guar gum).
  • the latter acts firstly as (co)stabilizer in an aqueous suspension of the powdered composition, and secondly cooperates, especially because of its swelling ability, synergistically with the other components of the composition by assisting the cathartic effect thereof, and additionally facilitates the processability of the composition of the invention to a fine-particle powder which can be directly dispersed in water.
  • an additional component namely the polygalactomannan-based polysaccharide or derivative thereof, is necessary in the aforementioned composition in order to achieve the desired properties. It is also possible in some cases to employ relatively high dosages.
  • the aforementioned composition by its nature as a powder is associated with a high dust content.
  • U.S. Pat. No. 4,511,561 A which likewise derives from the applicant describes a laxative in the form of granules which, besides plantago seeds ( plantaginis ovatae semen ) and/or plantago seed husks and senna fruits, also comprises gum tragacanth.
  • the problem addressed by the present invention is to provide a composition for use as laxative which at least substantially avoids the aforementioned disadvantages.
  • a further problem of the present invention is to provide a composition which can be used as laxative and which on the one hand shows a good cathartic effect but, at the same time, also makes it possible for administration to be facilitated and free of complications, in particular without the previously described problems and risks.
  • FIG. 1 shows the particle size distribution of the granules in one embodiment of the present invention.
  • FIG. 2 shows the particle size distribution of the granules in a second embodiment of the present invention.
  • FIG. 3 shows the particle size distribution of the granules in a third embodiment of the present invention.
  • FIG. 4 shows the particle size distribution of the granules in a fourth embodiment of the present invention.
  • FIG. 5 shows a flow diagram of the process for producing the senna fruit dry extract in a typical embodiment.
  • FIG. 6 shows a flow diagram of the method of the invention in a typical embodiment.
  • the applicant has now surprisingly found that the problem described previously can be solved by firstly providing the constituents of the senna fruits in the form of a senna fruit dry extract, and secondly dispensing with the incorporation of plantago seed husks, and employing exclusively plantago seed itself.
  • the present invention thus relates—according to a first aspect of the present invention—to a pharmaceutical composition which is suitable in particular for use as purgalive (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts:
  • the pharmaceutical composition of the invention shows by comparison with prior art compositions which employ dried and comminuted senna fruit themselves, as a result of the use of a senna fruit dry extract, an improved pharmacological and pharmaceutical activity with the same dosage amounts because of an increased active ingredient concentration in the senna fruit dry extract (i.e. concentration of hydroxyanthracene derivatives, especially sennosides).
  • the pharmaceutical composition of the invention even without the presence of an additional (co)stabilizer is stably suspendable or dispersible or soluble in water, and an aqueous suspension of the composition of the invention remains stable and thus drinkable over a lengthy period, i.e. the suspension leads to no premature phase separation, nor does it prematurely form a gel.
  • the suspendability or dispersibility is additionally improved and the problem and/or the risk of agglomerate formation is additionally reduced.
  • the senna fruit dry extract employed according to the invention normally comprises a content of hydroxyanthracene derivatives, based on the senna fruit dry extract, and in particular calculated as sennoside B, of at least 3% by weight, in particular at least 5% by weight, preferably at least 7% by weight, particularly preferably at least 8% by weight. It may nevertheless be necessary in individual cases or on the basis of the application to deviate from the aforementioned contents of hydroxyanthracene derivatives, especially sennosides, without departing from the scope of the present invention.
  • the senna fruit dry extract employed according to the invention normally comprises a content of hydroxyanthracene derivatives, especially sennosides, based on the senna fruit dry extract and in particular calculated as sennoside B, in the range from 3 to 30% by weight, in particular 5 to 25% by weight, preferably 7 to 20% by weight, particularly preferably 8 to 15% by weight, very particularly preferably 8 to 12% by weight.
  • the drug/extract ratio of the senna fruit dry extract employed can vary within relatively wide ranges: normally, the senna fruit dry extract used according to the invention has a drug/extract ratio of at least 2:1, in particular at least 2.5:1, preferably at least 3:1.
  • the drug/extract ratio of the senna fruit dry extract employed is generally in the range from 2:1 to 10:1, in particular 2.5:1 to 8:1, preferably 3:1 to 6:1. It may nevertheless be necessary in individual cases or based on the application to deviate from the aforementioned values without departing from the scope of the present invention.
  • the senna fruit dry extract is based on fruits of the Alexandria senna plant and/or of the Tinnevelly senna plant, it being possible also to employ mixtures of the two aforementioned senna plants in any mixing ratios.
  • the senna fruit dry extract employed according to the invention is normally obtainable by extracting fruits of the Alexandria senna plant and/or of the Tinnevelly senna plant. Details will be given in this regard about the extraction method in this regard, so that statements in this regard are unnecessary at this point.
  • the senna fruit dry extract employed according to the invention is advantageously designed to be soluble in water. This facilitates administration, because the senna fruit dry extract goes into solution on stirring with water and remains stable therein.
  • the senna fruit dry extract employed according to the invention generally comprises a mixture of different anthranoid compounds based on hydroxyanthracene derivatives, especially sennosides.
  • hydroxyanthracene derivatives in particular sennosides, are normally selected from the group of the following compounds of the general formula (I):
  • the hydroxyanthracene derivatives are selected from the group of the following compounds of the general formula (I) and mixtures thereof:
  • the pharmaceutical composition of the invention comprises the senna fruit dry extract in amounts of at least 1% by weight, in particular at least 2% by weight, preferably at least 3% by weight, particularly preferably at least 4% by weight, very particularly preferably at least 5% by weight, based on the composition.
  • the pharmaceutical composition of the invention generally comprises the senna fruit dry extract in amounts of from 1 to 15% by weight, in particular 2 to 10% by weight, preferably 3 to 8% by weight, particularly preferably 4 to 7% by weight, very particularly preferably 4.5 to 6.5% by weight, based on the composition. It may nevertheless be necessary in individual cases or based on the application to deviate from the aforementioned amounts without departing from the scope of the present invention.
  • the pharmaceutical composition of the invention generally has a total content of hydroxyanthracene derivatives, in particular sennosides, of at least 0.1% by weight, in particular at least 0.2% by weight, preferably at least 0.3% by weight, particularly preferably at least 0.4% by weight, very particularly preferably at least 0.5% by weight, based on the composition and in particular calculated as sennoside B.
  • the total content of hydroxyanthracene derivatives, in particular sennosides, in the composition of the invention, based on the composition and in particular calculated as sennoside B is normally from 0.1 to 2% by weight, in particular 0.2 to 1% by weight, preferably 0.3 to 0.8% by weight, particularly preferably 0.4 to 0.7% by weight. It may nevertheless be advantageous or necessary in individual cases or based on the application to deviate from the aforementioned amounts without departing from the scope of the present invention.
  • the content thereof ought to be, to achieve a good activity, at least 20% by weight, in particular at least 30% by weight, preferably at least 40% by weight, particularly preferably at least 50% by weight, very particularly preferably at least 60% by weight, based on the composition.
  • the plantago seed content in the composition of the invention is normally in the range from 20 to 90% by weight, in particular 30 to 90% by weight, preferably 40 to 85% by weight, particularly preferably 50 to 80% by weight, very particularly preferably 65 to 75% by weight.
  • the pharmaceutical composition of the invention is advantageously in the form of granules.
  • a number of advantages are associated therewith.
  • the granule form facilitates administration in several ways: firstly, dosage is facilitated (e.g. the granule form makes teaspoon dosage possible), and secondly the granule form increases on the one hand the storage stability of the composition, and on the other hand its suspendability or solubility in water for the relevant administration (i.e. stated more accurately the psyllium seed constituents go into suspension, while the other constituents, especially the senna fruit dry extract and, where appropriate, further ingredients such as, for example, granule formers, go into solution). It is also possible in this way to increase the stability of the prepared suspension or solution.
  • the granule form ensures that the composition of the invention is dust-free, which facilitates in particular the usability and minimizes the risks (e.g. inhalation on inappropriate use) connected therewith.
  • composition of the invention can in fact be processed to granules, because relevant attempts with comminuted constituents of senna fruits and psyllium constituents lead to agglomerations and pre-mature swelling. Only through the use of the senna fruit dry extract is it possible to convert the composition of the invention into granule form, which was not predictable in advance.
  • the pharmaceutical composition according to the present invention is in granule form, it normally comprises in addition (C) at least one granule former.
  • the granule former also referred to synonymously as granulation aid, granulating substance etc.—serves to a certain extent as matrix substance or, as it were, as “adhesive” for the ingredients to be granulated. Concerning this, details will be given below within the framework of the description of the manufacturing method of the invention, so that further statements are unnecessary at this point.
  • the amount of granule former employed in the pharmaceutical composition of the invention can vary within wide limits.
  • the pharmaceutical composition according to the invention normally comprises the granule former(s) in amounts of from 3 to 30% by weight, in particular 4 to 25% by weight, preferably 5 to 20% by weight, particularly preferably 6 to 15% by weight, very particularly preferably 7 to 10% by weight, based on the composition. Nevertheless, it may be necessary or advantageous in individual cases or based on the application to deviate from the aforementioned quantitative data without departing from the scope of the present invention.
  • Granule formers suitable for this purpose are known as such to the skilled worker.
  • the granule former employed according to the invention can be selected from the group of starch derivatives (e.g. starch degradation products, especially dextrins and maltodextrins, preferably maltodextrins), cellulose and cellulose derivatives (e.g. ethylcellulose), poly(meth)acrylic acids and poly(meth)acrylates (e.g. Eudragits® or carbomers, such as, for example, Carbopol®), gelatin, polyvinylpyrrolidone (PVP), polyalkylene glycols (e.g.
  • starch derivatives e.g. starch degradation products, especially dextrins and maltodextrins, preferably maltodextrins
  • cellulose and cellulose derivatives e.g. ethylcellulose
  • poly(meth)acrylic acids and poly(meth)acrylates e.g. Eudragits
  • polyethylene glycol such as, for example, Movicol®), dextrose (D-glucose), lactose, maltose and sugar substitutes (e.g. fructose and sugar alcohols such as, for example, mannitol, xylitol, sorbitol (D-glucitol), isomaltitol (isomalt), maltitol and lactitol), and mixtures thereof.
  • starch derivatives especially starch degradation products such as, in particular, dextrins and maltodextrins, particularly preferably maltodextrins.
  • starch degradation products such as, in particular, dextrins and maltodextrins, particularly preferably maltodextrins.
  • the granule former employed according to the invention should advantageously be water-soluble or at least water-dispersible, preferably water-soluble, in order on the one hand to be able to be sprayed as solution in the granulation, and on the other hand in order to be soluble in the drinking liquid on oral administration with water.
  • Granule formers which have proved to be particularly suitable are maltodextrins.
  • Maltodextrins are suitable as particularly stable matrix substances for building up the granules and ensure good adhesion or bonding of the individual ingredients and are additionally suitable in the preparation and administration because they ensure in particular an especially good and rapid solubility or suspendability of the corresponding drinking liquid, especially also in the cold state.
  • the composition of the invention is configured as granules
  • the granules are advantageously obtainable by fluidized bed granulation.
  • composition of the invention may additionally comprise at least one further additive, at least one further ingredient and/or one further added substance.
  • the latter can be selected in particular from the group of colorants such as natural or nature-identical colorants, flavorings, flavor enhancers and aromatizing agents, sweeteners, acidifiers, preservatives, stabilizers and costabilizers, electrolytes, minerals and mineral substances, vitamins, fillers, flow agents and processing aids, and mixtures of the aforementioned compounds.
  • the pharmaceutical composition according to the invention in particular in the form of granules, advantageously has a defined particle size and/or a defined particle size distribution.
  • the particle sizes can be determined by methods known per se, e.g. by sieve analysis, granulometry, by light diffraction, microscopy etc.
  • the following particle size data and particle size distribution data relate in particular to values from sieve analysis according to Ph. Eur. (Pharmacopoea Europea), 5th edition, Principal Volume 2005, page 298, section 2.9.12 “Sieve analysis [Sieb analyses]” (ISBN No. 3-7692-3638-6).
  • the pharmaceutical composition according to the present invention in particular in the form of granules, is generally at least substantially dust-free. This has not only advantages for manufacturing techniques, but also advantages in relation to use, because no agglomeration occurs when the composition of the invention is stirred into the drinking liquid and, moreover, inhalation is precluded even on inappropriate administration, and no premature swelling of the plantago seed takes place in the stored state.
  • the pharmaceutical composition according to the present invention in particular in the form of granules, has an average particle size in the range from 50 to 400 ⁇ m, in particular 50 to 300 ⁇ m, preferably 75 to 275 ⁇ m.
  • this enables problem-free manufacture and, on the other hand, this leads to good storage stability and to good stirrability into the administration liquid.
  • the chief mass fraction of the pharmaceutical composition according to the present invention preferably more than 55% by weight, in particular more than 60% by weight, or preferably more than 65% by weight, particularly preferably more than 70% by weight, very particularly preferably more than 75% by weight of the particles of the composition has particle sizes in the range from 50 to 1000 ⁇ m, preferably with a maximum of the distribution in particular at particle sizes in the range from 65 to 500 ⁇ m, preferably 125 to 450 ⁇ m.
  • the pharmaceutical composition according to the present invention in particular in the form of granules, has the following particle size distribution:
  • the pharmaceutical composition according to the present invention in particular in the form of granules, has the following particle size distribution (sieve spectrum according to sieve analysis):
  • the pharmaceutical composition according to the present invention advantageously has a bulk density in the range from 250 to 650 g/l, in particular 300 to 600 g/l, preferably 350 to 550 g/l, particularly preferably 400 to 500 g/l.
  • a bulk density in the range from 250 to 650 g/l, in particular 300 to 600 g/l, preferably 350 to 550 g/l, particularly preferably 400 to 500 g/l.
  • senna fruit dry extract achieves, by comparison with the prior art, a significantly higher hydroxyanthracene derivative content, in particular sennoside content, for the same dosage quantity, leading to the advantage that smaller amounts of the composition need to be administered than in the prior art to achieve a comparable effect, and this is not only desirable from the physiological viewpoint, but also minimizes the risk of hazards on inappropriate use (e.g. no risk of agglomeration if taken with too little liquid etc.).
  • a senna fruit dry extract also has a number of advantages for the techniques of manufacture and use: the use of a senna fruit dry extract distinctly facilitates the manufacture of the complete composition; the senna fruit dry extract can in particular be granulated better and more storage-stably than the dried and comminuted senna fruits.
  • a further advantage of the use of the senna fruit dry extract, in particular in the context of the composition of the invention in the form of granules, is the improved solubility or suspendability on oral use; in particular, the pharmaceutical composition can be converted into a stable suspension or solution whose consistency is substantially unchanged over several hours and thus remains ready for use over several hours.
  • the senna fruit dry extract employed according to the invention is water-soluble.
  • the composition of the invention being dust-free there are associated advantages for the technique of manufacture and in relation to use.
  • the present invention relates—according to a second aspect of the present invention—to a method for manufacturing the previously described pharmaceutical composition according to the present invention.
  • the previously defined active and/or other ingredients of the composition of the invention in particular (A) the senna fruit dry extract and (B) the plantago seed ( plantaginis ovatae semen ) and, where appropriate, further constituents of the composition as have been defined previously, where appropriate after previous adjustment of the particle sizes, in particular by means of commination, are subjected to a granulation, preferably in a fluidized-bed method, in the presence of (C) at least one previously defined granule former.
  • the granulation is normally additionally carried in the presence of a granulating liquid, generally water; as known as such to the skilled worker, the granulating liquid is introduced with a particular spraying rate, as will be described below.
  • the procedure for this is normally such that initially a powdered mixture of the active and other ingredients of the composition of the invention is prepared, it being advantageous for the particle sizes to be adjusted appropriately for the subsequent granulation.
  • the particle sizes in the initial powdered mixture are adjusted to below 200 ⁇ m, preferably below 150 ⁇ m.
  • the powdered mixture is then granulated, preferably by fluidized-bed granulation, normally fluidizing with an inlet air rate, in particular a machine-dependent inlet air rate, of about 200 to 300 m 3 /h and, after a suitable inlet air temperature has been reached, starting with the spraying in of the moisture, especially water or water vapor.
  • all the active and/or other ingredients of the composition of the invention can be introduced into the initial mixture in powder form. It is also possible alternatively—and this is preferred according to the invention—to introduce only part of the active and other ingredients, generally at least the senna fruit dry extract and the communicated plantago seeds, into the mixture in powder form, but to dissolve other constituents or ingredients, especially those soluble in water in the granulating liquid and combine them with the other constituents to give the relevant granules only during the granulation process.
  • the granulation is carried out in the presence of at least one previously defined granule former, i.e. normally the granule former is already present in the initial mixture in powder form, or else is—in a manner which is preferred according to the invention—dissolved in the granulating liquid to be introduced.
  • at least one previously defined granule former i.e. normally the granule former is already present in the initial mixture in powder form, or else is—in a manner which is preferred according to the invention—dissolved in the granulating liquid to be introduced.
  • the granulation generally takes place with a suitable spraying rate (ml/min), e.g. with an average set spraying rate of from 10 to 100 ml of granulating liquid per minute, and/or over a granulation time totaling from 30 to 300 minutes and/or at a granulation temperature in the range from 30 to 150° C., in particular 30 to 100° C. (e.g. machine-dependently for example also temperatures where appropriate different therefrom, in particular higher).
  • a suitable spraying rate e.g. with an average set spraying rate of from 10 to 100 ml of granulating liquid per minute
  • a granulation time totaling from 30 to 300 minutes and/or at a granulation temperature in the range from 30 to 150° C., in particular 30 to 100° C. (e.g. machine-dependently for example also temperatures where appropriate different therefrom, in particular higher).
  • composition of the invention can be converted in the manner described above into granules, because it would in principle have been expected that the plantago seed would agglomerate and swell prematurely. Surprisingly, however, these phenomena do not occur under the aforementioned granulation conditions, and granules can be produced in an efficient manner.
  • FIG. 6 shows in the form of a flow diagram in a diagrammatic overview of the method of the invention in a typical embodiment as has been described above and will also be represented below in the exemplary embodiments.
  • the senna fruit dry extract also referred to synonymously as senna pod dry extract—employed according to the invention is generally produced by transferring suitably comminuted senna pods or senna fruits based on Alexandria senna fruits and/or Tinnevelly senna fruits (either one variety in each case or in any mixing ratio) into percolators which are filled with cold water, connected in series and percolated upward. The percolate is subsequently collected in a dilute extract container and then heated by brief heating. The precipitated solids are removed in a separator. The dilute extract is concentrated with the aid of a vacuum falling-film evaporator. The concentrated extract is then ultra-pasteurized in an ultra-pasteurization system.
  • the spray solution is then mixed with carbon dioxide and dried in a spray tower.
  • the sprayed product is mixed in a mixer, in particular in an orbiting screw mixer, and—where appropriate after intermediate storage—passed on for subsequent manufacture of the composition of the invention.
  • the senna fruit dry extract employed according to the invention is soluble in water. A diagrammatic overview of the process for producing the senna fruit dry extract is depicted in FIG. 5 .
  • composition according to the present invention is suitable in particular for use as laxative (cathartic, purgative).
  • the present invention thus relates—according to a third aspect of the present invention—to the use of the pharmaceutical composition described above as laxative (purgative, cathartic) and to the use of the pharmaceutical composition according to the present invention described above for the manufacture of a medicament or of a pharmaceutical composition for promoting and/or facilitating and/or regulating bowel evacuation and/or bowel activity.
  • the pharmaceutical composition according to the present invention can be employed in particular for the prophylactic or curative treatment of disorders in which easy defecation with light stool, in particular for hemorrhoidal disorders, conditions following rectal/anal surgical procedures and before and after surgical procedures on the abdominal cavity, and for constipation, or for facilitating passage through the bowel and defecation, in particular for alleviating the side effects of therapy with constipation-causing medicaments.
  • the composition of the invention is taken orally, preferably as aqueous suspension or solution, in particular in single doses of from 1 to 5 g, in particular 2 to 4 g, preferably 2.5 to 3.5 g.
  • Normal daily doses are in the range of in total from 1 to 50 g, preferably 1 to 20 g, particularly preferably 3 to 10 g, of the composition of the invention.
  • composition of the invention can, for the purposes of simplified administration, be provided in pack units (e.g. sachets) for the appropriate single doses (e.g. sachets containing 1 to 5 g). Because the composition of the invention, in particular in the form of granules, is easily meterable, the composition of the invention can, however, also be provided in large containers (e.g. cans with 40 to 1000 g) because it is possible with the composition of the invention easily to use a teaspoon for dosage.
  • pack units e.g. sachets
  • single doses e.g. sachets containing 1 to 5 g.
  • the present invention further relates—according to a fourth aspect of the present invention—to a method for treating the human body, in particular for the purposes of prophylactic or curative treatment of disorders and conditions of the aforementioned type, where in the context of the method of the invention a pharmaceutically or pharmacologically effective amount of the composition according to the present invention described above is administered, preferably orally, in particular in the form of an aqueous suspension or solution.
  • Senna fruit dry extract (10%) 506.67 g Plantago seeds (maximum particle size: 140 ⁇ m) 7,000 g Colorant 76 g Aromatizing substance 400 g Sweetener 28 g Granule former (maltodextrin) 836 g Acidifier (citric acid, anhydrous) 1,153 g Water (granulating liquid) 4 kg A powdered mixture was produced from the plantago seeds, the senna fruit dry extract and the aromatizing substance. The other raw materials were dissolved in water; the solution was clear and was subsequently used as granulating liquid.
  • a fluidized-bed granulation was subsequently carried out.
  • the powdered mixture was transferred into the fixed-bed granulation. 200 to 300 m 3 /h was used for fluidization.
  • spraying was started. The inlet air temperature rose during the process up to 85° C.
  • the product temperature was up to 60° C. at intermediate times, averaging 40 to 50° C.
  • the granulation took place with an average adjusted spraying rate of 46 ml/min, equivalent to an actual spraying rate of 29.7 g of granulating liquid/minute.
  • the total time was 145 minutes.
  • the resulting granules were dried for about 1 hour until the loss on drying was less than 5%.
  • the maximum product temperature was 60° C.
  • the yield was 8 kg.
  • the particle size distribution of the resulting granules is shown in FIG. 1 .
  • compositions of the invention with different flavors were also produced in a corresponding manner (e.g. apple and cherry).
  • the senna fruit dry extract employed according to the invention was produced as follows: the suitable comminuted senna fruits were put into percolators; the percolators were filled with cold water, connected in series and percolated upward. The percolate was then collected in the dilute extract container and subsequently heated by brief heating. The precipitated solids were removed in a separator, and the dilute extract was concentrated using a vacuum falling-film evaporator, and the concentrated extract was subsequently ultra-pasteurized in an ultra-pasteurization system. For quality control, samples were taken to determine the dry matter content. This was followed by spray drying in a spray tower, with carbon dioxide having been added to the spray solution.
  • the sprayed product was mixed in an orbiting screw mixer, the mixture was weighed and put into temporary packages until employed in the manufacturing method of the invention.
  • the weight per liter of the senna fruit dry extract produced in this way was in the range from 100 to 300 g/l, and the bulk density was in the range from 200 to 400 g/l.
  • the initial senna fruit mixture employed was a 50:50 mixture of Alexandria senna fruits and Tinnevelly senna fruits.
  • the resulting senna fruit dry extract had a content of hydroxyanthracine derivatives, calculated as sennoside B and based on the senna fruit dry extract, of 10%.
  • a composition of the invention manufactured as above, and two prior art comparative products, are converted into an aqueous suspension.
  • 5 g of the compositions are stirred into portions of about 200 ml of tap water.
  • the first comparative composition is a powdery commercial product based on Indian plantain husks (psyllium) which comprises in addition further ingredients (inter alia natural and synthetic colorants, flavorings, aromatizing agents and sweeteners, citric acid, iron oxide and calcium) but is free of sennosides.
  • Indian plantain husks psyllium
  • further ingredients inter alia natural and synthetic colorants, flavorings, aromatizing agents and sweeteners, citric acid, iron oxide and calcium
  • a fine-particle powder more than 70% by weight of the particles with average diameters in the range from 125 to 250 ⁇ m
  • the composition of the invention and the second comparative composition which corresponds to the applicant's own DE 103 46 083 A1
  • the comparative suspension with the first comparative composition shows phase separation after only a few minutes and, after a quarter of an hour, has formed a gel and a thick, undrinkable agglomerate on the surface
  • the first comparative composition also shows disadvantages through its insipid taste and artificial appearance.
  • the aqueous suspension with the second comparative composition according to DE 103 46 083 A1 also showed phase separation, whereas the aqueous suspension with the composition of the invention still showed no phase separation and moreover remained phase-stable and drinkable for several hours more.
  • the aforementioned three compositions differ significantly in their laxative effect.
  • the first comparative composition based on Indian plantain husks (psyllium) shows only a moderate cathartic effect, which is not always adequate in severe cases of constipation
  • the second comparative composition shows a distinctly better cathartic effect because of the combination of physical effect of the plantago seeds/plantago seed husks as a result of swelling on the one hand and pharmacologically stimulating action of the sennosides on the other hand, although accurate dosage with a teaspoon is not possible owing to the mixture being in powder form, and on the other hand the danger of risks (e.g. agglomeration) cannot be precluded on inappropriate administration.
  • composition of the invention Only with the composition of the invention is dosage with a teaspoon possible, because of the granule form, and premature agglomeration even on inappropriate use is at least substantially precluded; in addition, as a result of the use of senna fruit dry extract the concentration of sennosides is increased to such an extent that a distinctly smaller amount is needed to be taken (specifically about one half) to achieve a comparable laxative effect, thus further minimizing the risk even on inappropriate use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/040,290 2007-05-02 2008-02-29 Pharmaceutical composition for use as a laxative Abandoned US20080311210A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/140,102 US20090110759A1 (en) 2007-05-02 2008-06-16 Pharmaceutical Composition for Use as a Laxative
US12/420,602 US7611736B2 (en) 2007-05-02 2009-04-08 Pharmaceutical composition for use as a laxative

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102007020842 2007-05-02
DE102007020842.3 2007-05-02
DE102007023397.5A DE102007023397B4 (de) 2007-05-02 2007-05-18 Neue pharmazeutische Zusammensetzung zur Verwendung als Laxativum
DE102007023397.5 2007-05-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/140,102 Continuation US20090110759A1 (en) 2007-05-02 2008-06-16 Pharmaceutical Composition for Use as a Laxative

Publications (1)

Publication Number Publication Date
US20080311210A1 true US20080311210A1 (en) 2008-12-18

Family

ID=39809738

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/040,290 Abandoned US20080311210A1 (en) 2007-05-02 2008-02-29 Pharmaceutical composition for use as a laxative
US12/140,102 Abandoned US20090110759A1 (en) 2007-05-02 2008-06-16 Pharmaceutical Composition for Use as a Laxative
US12/420,602 Expired - Fee Related US7611736B2 (en) 2007-05-02 2009-04-08 Pharmaceutical composition for use as a laxative

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/140,102 Abandoned US20090110759A1 (en) 2007-05-02 2008-06-16 Pharmaceutical Composition for Use as a Laxative
US12/420,602 Expired - Fee Related US7611736B2 (en) 2007-05-02 2009-04-08 Pharmaceutical composition for use as a laxative

Country Status (15)

Country Link
US (3) US20080311210A1 (fr)
EP (1) EP2139505B1 (fr)
JP (1) JP5327682B2 (fr)
KR (1) KR101149431B1 (fr)
CN (1) CN101687003B (fr)
AU (1) AU2008249047B2 (fr)
BR (1) BRPI0810986B1 (fr)
CA (1) CA2684813C (fr)
DE (1) DE102007023397B4 (fr)
ES (1) ES2501966T3 (fr)
HK (1) HK1136963A1 (fr)
MX (1) MX2009011767A (fr)
PT (1) PT2139505E (fr)
RU (1) RU2420302C1 (fr)
WO (1) WO2008135115A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8523637B2 (en) * 2009-07-21 2013-09-03 Dustless Depot, Llc Angle grinder dust shroud with slideable access hatch
JP5842521B2 (ja) * 2011-09-30 2016-01-13 ゼリア新薬工業株式会社 便秘改善薬
JP6116174B2 (ja) * 2012-09-27 2017-04-19 小林製薬株式会社 便通改善用経口組成物
CN104642869B (zh) * 2015-01-28 2017-09-26 四川健之源科技有限公司 一种具有通便功能的保健食品
CN109528733A (zh) * 2019-01-18 2019-03-29 南京医科大学第二附属医院 葡萄糖在制备治疗结肠动力障碍性疾病药物中的应用及药物试剂盒

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2278464A (en) * 1938-09-20 1942-04-07 Food Mfg Corp Medicinal preparation
US4511561A (en) * 1980-01-16 1985-04-16 Dr. Madaus & Co. Laxative composition comprising psyllium seeds and senna fruits
US5173296A (en) * 1990-11-16 1992-12-22 The Procter & Gamble Company Compositions containing psyllium
US5232698A (en) * 1992-06-12 1993-08-03 The Proctor & Gamble Company Psyllium drink mix compositions
US5232699A (en) * 1990-07-26 1993-08-03 The Proctor & Gamble Company Laxative compositions
US5258181A (en) * 1992-03-02 1993-11-02 The Procter & Gamble Company Compositions containing psyllium
US5320847A (en) * 1993-05-13 1994-06-14 Valentine Enterprises, Inc. Agglomerated psyllium hydrophilic mucilloid combinates
US5340580A (en) * 1989-08-10 1994-08-23 The Procter & Gamble Company Agglomerated psyllium husk containing edible acid
US20040009234A1 (en) * 2002-07-10 2004-01-15 Meisel Gerard M. Gastrointestinal compositions
US6709678B2 (en) * 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
US20050053676A1 (en) * 2003-09-05 2005-03-10 Madaus Ag Powdered composition for use as laxative
US20050129781A1 (en) * 2003-11-19 2005-06-16 Stephen Skiendzielewski Colonic purgative composition with soluble binding agent
US20080008741A1 (en) * 2004-02-03 2008-01-10 Eyal Raz Methods of Treating Irritable Bowel Syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1103520B (de) 1959-08-12 1961-03-30 Madaus & Co Dr Verfahren zur Herstellung eines Abfuehrmittels
DE3001357C2 (de) * 1980-01-16 1986-08-21 Dr. Madaus & Co, 5000 Koeln Granuliertes Abführmittel auf der Basis von Plantagosamen und Sennesfrüchten und Verfahren zur Herstellung desselben
US4548806A (en) * 1982-07-23 1985-10-22 G. D. Searle & Co. Psyllium hydrophilic mucilloid composition
US4595592A (en) * 1984-03-21 1986-06-17 Dr. Madaus & Co. Process for obtaining laxative compounds from senna drugs
DK0387933T3 (da) * 1989-03-16 1993-12-06 Procter & Gamble Psylliumholdige, bagte småkagesammensætninger
FR2646352B3 (fr) * 1989-04-28 1991-09-06 Chicouri Marcel Nouvelles compositions pharmaceutiques pour le traitement de la constipation et leur procede d'obtention
JPH03190821A (ja) * 1989-12-19 1991-08-20 Lion Corp 顆粒状ないし粒状緩下剤組成物
RU2134044C1 (ru) 1997-07-31 1999-08-10 Закрытое акционерное общество "Эвалар" Биологически активная добавка к пище "фитолакс" и способ ее получения
RU2264223C2 (ru) 2000-10-23 2005-11-20 Открытое Акционерное Общество "Фармацевтическая Фабрика Санкт-Петербурга" Микстура слабительная сухая, слабительное средство, препаративная форма микстуры слабительной сухой и способ приготовления микстуры слабительной
DE10346083A1 (de) 2003-09-05 2005-04-07 Madaus Ag Pulverförmige Zusammensetzung zur Verwendung als Laxativum
WO2007013093A2 (fr) * 2005-04-01 2007-02-01 Shiv Prakash Formulation laxative
ES2320827B1 (es) * 2006-12-29 2010-03-03 Madaus, S.A. "composicion farmaceutica que contiene psyllium y senna".

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2278464A (en) * 1938-09-20 1942-04-07 Food Mfg Corp Medicinal preparation
US4511561A (en) * 1980-01-16 1985-04-16 Dr. Madaus & Co. Laxative composition comprising psyllium seeds and senna fruits
US5340580A (en) * 1989-08-10 1994-08-23 The Procter & Gamble Company Agglomerated psyllium husk containing edible acid
US5232699A (en) * 1990-07-26 1993-08-03 The Proctor & Gamble Company Laxative compositions
US5173296A (en) * 1990-11-16 1992-12-22 The Procter & Gamble Company Compositions containing psyllium
US5258181A (en) * 1992-03-02 1993-11-02 The Procter & Gamble Company Compositions containing psyllium
US5232698A (en) * 1992-06-12 1993-08-03 The Proctor & Gamble Company Psyllium drink mix compositions
US5320847A (en) * 1993-05-13 1994-06-14 Valentine Enterprises, Inc. Agglomerated psyllium hydrophilic mucilloid combinates
US6709678B2 (en) * 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
US20040009234A1 (en) * 2002-07-10 2004-01-15 Meisel Gerard M. Gastrointestinal compositions
US20050053676A1 (en) * 2003-09-05 2005-03-10 Madaus Ag Powdered composition for use as laxative
US20050129781A1 (en) * 2003-11-19 2005-06-16 Stephen Skiendzielewski Colonic purgative composition with soluble binding agent
US20080008741A1 (en) * 2004-02-03 2008-01-10 Eyal Raz Methods of Treating Irritable Bowel Syndrome

Also Published As

Publication number Publication date
US7611736B2 (en) 2009-11-03
HK1136963A1 (en) 2010-07-16
KR101149431B1 (ko) 2012-07-11
US20090186106A1 (en) 2009-07-23
DE102007023397A1 (de) 2008-11-06
CA2684813C (fr) 2013-10-29
AU2008249047A1 (en) 2008-11-13
EP2139505B1 (fr) 2014-06-25
PT2139505E (pt) 2014-09-17
CA2684813A1 (fr) 2008-11-13
WO2008135115A3 (fr) 2009-04-02
DE102007023397B4 (de) 2015-03-26
CN101687003B (zh) 2013-01-02
JP2010524982A (ja) 2010-07-22
US20090110759A1 (en) 2009-04-30
BRPI0810986B1 (pt) 2021-11-23
RU2420302C1 (ru) 2011-06-10
BRPI0810986A2 (pt) 2015-01-27
MX2009011767A (es) 2010-02-17
WO2008135115A2 (fr) 2008-11-13
JP5327682B2 (ja) 2013-10-30
CN101687003A (zh) 2010-03-31
AU2008249047B2 (en) 2013-07-04
EP2139505A2 (fr) 2010-01-06
KR20100007894A (ko) 2010-01-22
ES2501966T3 (es) 2014-10-02

Similar Documents

Publication Publication Date Title
US7611736B2 (en) Pharmaceutical composition for use as a laxative
EP2005945A2 (fr) Granule de phosphate d'oseltamivir et son procédé de préparation
EP2990042A1 (fr) Composition comprenant un fructooligosaccharide et un glycoside de quercétine
CN1785340A (zh) 一种复方牛黄清胃快速分散固体制剂及其制备方法
EP1663273B1 (fr) Composition pulverulente servant de laxatif
CN100542529C (zh) 水溶性水飞蓟素组合物及其制备方法
CN1785336A (zh) 一种通幽润燥快速分散固体制剂及其制备方法
KR20200092720A (ko) 노니 추출물 또는 이로부터 분리한 스코폴레틴을 유효성분으로 함유하는 통풍 예방 또는 치료용 약학적 조성물
EP1697050B1 (fr) Fractions riches en fibres de semences de trigonella foenum-graceum et leurs utilisations comme excipient pharmaceutique
CN115475227A (zh) 治疗痛风的药物组合物及剂型
CN100515399C (zh) 一种左金快速分散固体制剂及其制备方法
CN100515400C (zh) 一种保和快速分散固体制剂及其制备方法
DE20315266U1 (de) Pulverförmige Zusammensetzung zur Verwendung als Laxativum
WO2008080809A2 (fr) Composition pharmaceutique contenant du psyllium et du senna
CN100534417C (zh) 一种柏子仁快速分散固体制剂及其制备方法
ES2361923T3 (es) Procedimiento para la preparación de un extracto medicinal que contiene hidroxiestilbeno.
DE10008990A1 (de) Milchfreies prebiotisches Instantpulver
CN114652839A (zh) 一种含二氧化碳的共处理辅料及其制备方法
DE202007007143U1 (de) Neue pharmazeutische Zusammensetzung zur Verwendung als Laxativum
CN115006416A (zh) 落新妇苷在制备用于治疗息肉药物中的应用
CN114947124A (zh) 具有缓解痛风作用的固体组合物及其制备方法
CN1785298A (zh) 一种麻仁润肠快速分散固体制剂及其制备方法
CN112423735A (zh) 香叶木苷或类黄酮级分的咀嚼片形式的药物组合物
CN1785341A (zh) 一种女科十珍快速分散固体制剂及其制备方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: MADAUS GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORRICK, WOLFGANG, DR.;PRENNER, LARS-NORBERT, DR.;HUBBERT, MICHAEL, DR.;AND OTHERS;REEL/FRAME:020804/0257;SIGNING DATES FROM 20080322 TO 20080328

AS Assignment

Owner name: MADAUS GMBH, GERMANY

Free format text: PLEASE;ASSIGNORS:MORICK, WOLFGANG;PRENNER, LARS-NORBERT;HUBBERT, MICHAEL;AND OTHERS;REEL/FRAME:020975/0578;SIGNING DATES FROM 20080322 TO 20080328

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION